People
People & Governance: A Board That Fires People, Pay That Actually Falls
The verdict in one sentence: Molina is one of the rare large-caps where the governance machinery genuinely bites — an independent board that once fired the founding family, a pay program whose "actually-paid" value turned negative when the stock halved, no pledging and a real clawback — yet 2025 exposed its soft spot: a 40% say-on-pay revolt over an outsized retention grant to a 69-year-old CEO with no named successor, against a stock that fell ~40% in a single year.
This is not a founder-control story. At its 2003 IPO the Molina family beneficially owned roughly 74% of the company [1]; today insiders as a group own just 1.44% [2]. The whole governance question has flipped: not "can a controlling family be checked?" but "can a fully independent board hold an entrenched, highly-paid professional CEO accountable when results crater?" The evidence says mostly yes — with one loud asterisk.
Governance Grade
Insider Ownership (%)
2025 Say-on-Pay Support (%)
CEO Pay Ratio (x median)
Sources: insider ownership and pay ratio — 2026 Proxy [3] [4]; say-on-pay result — 2026 Proxy [5].
From Family Fiefdom to Institutional Float — and a Board That Proved It Will Act
Molina was founded in 1980 by emergency-room physician C. David Molina as a Medicaid clinic network [6], and went public in 2003 still controlled by his family, who held ~74% of the stock with directors and officers at ~32.4% [7]. The pivotal governance event came in May 2017, when the board ousted the two founder-sons — CEO Dr. J. Mario Molina and CFO John Molina — installed Dale B. Wolf as independent Chairman and Ronna Romney as Vice-Chair, and launched an outside CEO search that landed Joseph Zubretsky that November. (The 2017 firing of the founding family is documented in the company's own May 2017 leadership-change announcement and contemporaneous press reporting; it is the inflection point that produced today's board structure.)
That history matters because it is the strongest single data point a governance analyst can have: this board has already demonstrated, at maximum stakes, that it will remove leadership that underperforms. Wolf has chaired the board as an independent director continuously since that May 2017 transition [8].
Today's ownership is entirely institutional float — index and active managers, none controlling:
Source: 2026 Proxy, Security Ownership of Principal Stockholders and Management [9] [10].
Green flag: A board that fired its own founders, separated Chairman and CEO with an independent Chairman, and runs on 100% institutional float carries none of the entrenchment risk typical of family- or founder-controlled peers.
The People: A Turnaround CEO at 69, and a Bench You Can't Fully See
Joseph M. Zubretsky, 69, has been President & CEO since November 2017 — recruited from senior strategy, operating and finance roles at Aetna and The Hanover Group, and credited in the proxy with leading Molina's "turnaround and growth" [11]. The growth is real: revenue roughly $28B in 2021 to $45B in 2025, even as 2025 earnings cratered (more below).
Source: 2026 Proxy, 2025 Summary Compensation Table [12].
The capability case is strong: a CFO (Keim) and COO (Woys) who have been NEOs through the entire turnaround, a long-tenured legal chief, and a Medicaid-segment EVP. But the single most important people-risk is succession around the CEO. Investors themselves raised it: the proxy discloses that in late 2024, "in response to direct stockholder inquiries regarding the age of Mr. Zubretsky and the expected duration of his remaining tenure," the board cut a special retention grant to keep him through at least year-end 2027 [13]. A 69-year-old CEO retained by golden handcuffs, with no successor named in the proxy, is real key-man risk. The parallel (smaller) retention award to CFO Keim hints the board sees him as a candidate, but that is inference, not disclosure.
Compensation: Big On Paper, Brutal In Reality
This is the part Molina gets structurally right. On a granted basis, CEO 2025 total pay was $18.34M — 88% equity, a $1.6M salary, and a $0 cash bonus because short-term targets were missed [14]. Against $45B of revenue the absolute number is mid-pack for a Fortune-500 managed-care CEO; the structure is almost entirely at-risk equity.
Source: 2026 Proxy, 2025 Summary Compensation Table [15].
But "granted" pay overstates reality dramatically. The proxy's own SEC-mandated Compensation Actually Paid (CAP) — which marks equity to the stock price — shows the CEO's realizable pay collapsing in lockstep with the share price, going negative ($15.3M) in 2025:
Source: 2026 Proxy, Pay Versus Performance table [16].
The alignment is mechanical and unforgiving. The 2023 PSUs were forfeited entirely (performance missed), and management now states the 2024 and 2025 PSUs are not probable to vest and carry a fair value of zero at December 31, 2025 [17]. Crucially, no awards were repriced or modified to soften that outcome [18]. Pay fell because performance fell — which is exactly what a pay program is supposed to do.
And performance did fall, hard. Net income halved, and total shareholder return diverged violently from peers in 2025:
Source: 2026 Proxy, Pay Versus Performance — Company vs Peer Group TSR [19].
A $100 investment in MOH at end-2020 peaked at ~$170 (end-2023) and ended 2025 at $81.60 — below where it started — while the peer group climbed to $161.89 [20]. The CEO pay ratio is 228:1 on a granted basis, but the proxy notes that excluding the PSUs it believes will be forfeited, the ratio is effectively 107:1, against a median employee pay of $80,329 [21].
The Asterisk: A 40% Say-on-Pay Revolt
For all that structural alignment, shareholders rejected Molina's pay program in April 2025 — only 40% of votes cast supported say-on-pay, after that vote had averaged over 90% support in the prior five years [22] [23]. That is a genuine governance event, not a rounding error.
The trigger, per the board's own post-mortem, was a one-time special retention grant made in fall 2024 — 146,184 PSUs to the CEO and 53,074 PSUs to the CFO — vesting only if Molina hits ~$36 of adjusted EPS in FY2027 (a cumulative growth rate above 15%), with zero payout below a $32 threshold [24]. Investors objected both to the magnitude of a special off-cycle grant stacked on top of ordinary annual equity, and to thin disclosure of how it related to the regular program [25].
How the board responded is to its credit: Chairman/Comp-chair Wolf personally led an engagement program contacting holders of ~77% of shares and holding substantive talks with ~64% across 15+ meetings [26] [27]. The board's defense is that the very grant that caused the revolt is now expected to pay nothing — proof, it argues, that the program is working [28].
The unresolved tension: The board is partly right — the retention PSUs will likely forfeit, so the "windfall" never materializes. But a 40% vote is shareholders objecting to the design decision (a large off-cycle handcuff for an aging CEO), not just the outcome. That the grant won't pay does not retroactively make granting it good governance. Watch the 2026 say-on-pay vote for whether trust has been rebuilt.
Alignment & Skin in the Game: Strong Rules, Mixed Behavior
The rules are best-in-class. The insider-trading policy flatly prohibits directors and officers from pledging shares (including margin accounts), and the proxy confirms none had any pledge outstanding; Molina also runs an anti-hedging policy, a Dodd-Frank-compliant clawback, and stock-ownership guidelines that all NEOs satisfied at year-end 2025 [29]. On the spectrum from "formal alignment" to "real skin in the game," the absence of pledging is a clear positive.
Insider behavior, however, sends a more mixed signal. Open-market activity over 2024–2026 was net selling, dominated by one transaction: CEO Zubretsky sold ~$28.0M of stock at ~$320 on April 30, 2025 — a discretionary (non-10b5-1) sale, executed near the stock's peak and just as the say-on-pay vote was failing, months before the collapse to ~$155 by August and ~$125 by early 2026.
Source: SEC Form 4 filings, as compiled [30].
The mitigating, and arguably more telling, signal is who bought the dip: COO James Woys purchased ~$1.56M of stock in August 2025 at ~$156, and director Richard Zoretic added ~$100K at ~$125 in February 2026 [31]. Operating leadership buying after the crash is a stronger conviction signal than the CEO's pre-crash sale is a negative one — but the optics of a $28M discretionary CEO sale at the top, in a year of a failed pay vote, deserve to be named plainly.
Director ownership is modest in dollar terms but reinforced by an all-equity-leaning fee structure: non-employee directors receive a $125,000 cash retainer plus a $220,000 annual equity grant that vests immediately, with the Chairman earning $650,141 in total 2025 compensation [32] [33].
Board Quality: Genuinely Independent, Deep Healthcare Bench
The board has determined that every director and nominee except CEO Zubretsky is independent under NYSE and SEC rules — nine of ten — with the Chairman and CEO roles split under an independent Chairman [34] [35]. The bench is unusually heavy with operators who have actually run managed-care businesses — ex-CEOs of Coventry Health Care, eHealth, and senior executives of WellPoint, Aetna/CVS, and Amerigroup — not just generalist directors.
Source: 2026 Proxy, Director Nominees and board data [36] [37].
Tenure is the one area to watch for "formal vs genuine" independence: independent-director tenure ranges from 1 to 23 years, with four directors over ten years (Romney since 2003, Orlando since 2005) [38]. NYSE independence tests treat long tenure as permitted, but very long service can dull independence in practice. Molina's mitigant is structural: it adopted 12-year term limits for directors first elected after 2020 and is actively refreshing — Grohowski (2025) and Soistman (2026 nominee) are recent additions sourced via a third-party search firm [39] [40]. The two longest-serving directors, however, are exempt from those limits.
Related-Party Risk: Effectively Nil
For a company this size, the related-party footprint is remarkably clean. The proxy discloses exactly one related-person transaction in 2025: Vice-Chair Ronna Romney's son, George Romney, is employed by the company at an annual base salary of ~$157,590 — disclosed and ratified under the related-party policy [41]. That is a minor, fully-disclosed employment relationship, not a value-transfer concern. There are no founder leases, no promoter loans, no inter-company dealings — the residue of a company that severed its family ties in 2017.
Verdict: B+ — The Machinery Works; The Judgment Slipped Once
Molina earns a B+. The governance fundamentals are strong and, unusually, tested: a fully independent board that fired its founders, a split independent chairmanship, no pledging or hedging, a real clawback, NEOs who meet ownership guidelines, and — most importantly — a pay program where "actually paid" compensation went negative as the stock halved and where PSUs were left to forfeit rather than repriced. Related-party risk is negligible. This is a board with both the structure and the demonstrated willingness to hold management accountable.
What keeps it from an A is the 2025 say-on-pay revolt and what sits underneath it: a board that, facing investor anxiety about a 69-year-old CEO's tenure, reached for a large off-cycle retention grant rather than a visible succession plan — and got a 40% vote for its trouble. The CEO's ~$28M discretionary sale near the top, in that same window, doesn't help the optics.
The single thing most likely to move the grade: the 2026 say-on-pay vote and CEO-succession clarity. A return to majority (ideally 80%+) say-on-pay support, paired with a named or visibly-developed successor, would push this toward an A-. A second failed vote, or a disorderly transition when Zubretsky eventually departs, would pull it to B-/C+. The structure is excellent; the open question is whether the board's judgment on its single most important decision — who runs the company next — matches the rigor of its pay machinery.